Skip to main content

Thrombosed AV grafts

Not indicated for use in Canada.

Arteriovenous (AV) access grafts that have thrombosed are often associated with worse outcomes than those that are stenosed1

  • The 2019 KDOQI guidelines for vascular access specify a target goal of ≤ three interventions annually to maintain access2:

    • In support of achieving this goal, KDOQI recommends stent grafts in preference to angioplasty alone for recurrent thrombotic AV access lesions.

There are a limited number of randomized trials to help guide evidence-based treatment decisions for patients with thrombosed grafts

  • In the Gore REVISE Clinical Study, 43% of patients in the GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface* arm of the study enrolled with a thrombosed graft.1 

The GORE® VIABAHN® Endoprosthesis has proven success when treating thrombosed grafts1, 2 

Proven patency

  • Exceeded KDOQI minimum guidelines for three-month circuit primary patency for thrombotic patients (48%) whereas percutaneous transluminal angioplasty (PTA) did not (39%).1,2
  • Increased primary patency in thrombosed grafts of both the target lesion and the circuit by ~50% when compared to PTA at six months.1

Fewer reinterventions

  • Lowered the mean number of interventions over two years by 40% in thrombosed grafts.3

AV access maintenance challenges

  • The GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface has proven success in the most challenging AV access cases, including early PTA failures, lesions at points of flexion, and in thrombosed grafts.

Learn more.

* As used by Gore, Heparin Bioactive Surface refers to Gore’s proprietary CBAS® Heparin Surface.

† Also referred to as the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface in some regions.

  1. Vesely T, DaVanzo W, Behrend T, Dwyer A, Aruny J. Balloon angioplasty versus Viabahn stent graft for treatment of failing or thrombosed prosthetic hemodialysis grafts. Journal of Vascular Surgery 2016;64(5):1400-1410.e1.
  2. Lok CE, Huber TS, Lee T, et al; KDOQI Vascular Access Guideline Work Group. KDOQI Clinical Practice Guideline for Vascular Access: 2019 update. American Journal of Kidney Diseases 2020;75(4)Supplement 2:S1-S164.
  3. Mohr BA, Sheen AL, Roy-Chaudhury P, Schultz SR, Aruny JE; REVISE Investigators.  Clinical and economic benefits of stent grafts in dysfunctional and thrombosed hemodialysis access graft circuits in the REVISE Randomized Trial.  Journal of Vascular & Interventional Radiology 2019;30(2):203-211.e4.

Refer to Instructions for Use at for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. RXOnly

eIFU Symbol